Tags : Akcea

PharmaShots Weekly Snapshot (January 27-31, 2020)

ProQR’s QR-421a Receives FDA’s Rare Pediatric Disease Designation for Retinitis Pigmentosa Published: Jan 30, 2020 | Tags: ProQR, QR-421a, Receives, FDA, Rare Pediatric Disease Designation, Retinitis Pigmentosa 2. Eli Lilly’s Fast-Acting Insulin Lispro Receives CHMP’s Positive Opinion in Patients with Diabetes Published: Jan 31, 2020 | Tags: Eli Lilly, Fast Acting Insulin Lispro, Receives, CHMP, Positive Opinion, […]Read More

Akcea and Ionis Report Results of AKCEA-ANGPTL3-LRx in P-II Study

Shots: The P-II study involves assessing AKCEA-ANGPTL3-LRx (SC, 40-80mg) vs PBO in 105 patients with hypertriglyceridemia, T2D, and NAFLD for 6mos. The P-II study resulted in meeting its primary & multiple secondary endpoints with a reduction in fasting triglycerides, ANGPTL3, apoC-III, VLDL-C, non-HDL cholesterol, no reduction in liver fat and is well tolerated AKCEA-ANGPTL3-LRx is […]Read More

Novartis Terminates its Agreement with Akcea for AKCEA-APOCIII-LRx

Shots: Akcea retains exclusive rights to develop and commercialize AKCEA-APOCIII-LRx following Novartis’ decision for not exercising the option In 2017, Novartis signed an option agreement with Akcea for two antisense therapies AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx for cardiovascular disease. In Feb 2019 Novartis exercised its option for AKCEA-APO(a)-LRx due to strategic portfolio reason , further decided not […]Read More

Pfizer Signs an Exclusive Worldwide License Agreement with Akcea for

Shots: Akcea and Ionis to receive $250M, up to $1.3B as development, regulatory and commercial milestone with royalties on global sales of AKCEA-ANGPTL3-L(Rx) splitting equally b/w the companies. Akcea will settle its $125M obligations to Ionis in Akcea common stock Pfizer will be responsible for all development and regulatory activities and costs after P-II study. […]Read More

Novartis Exercises its Option to License AKCEA-APO(a)-LRx from Akcea

Shots: Akcea to receive $150M as option license fee with equal sharing with Ionis as equity investment in Akcea. Novartis to get exclusive WW development and commercialization rights for Akcea’s AKCEA-APO(a)-LRx (TQJ230) and will initiate P-III trial for cardiovascular outcomes In Jan,2107 Akcea and its subsidiary Ionis collaborated with Novartis to develop & commercialize AKCEA-APO(a)-LRx […]Read More